Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06324994
Other study ID # YY-20394-BV-MCL
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date May 1, 2024
Est. completion date December 1, 2026

Study information

Verified date March 2024
Source Dalian Medical University
Contact Xiuhua Sun, Doctor
Phone +86 17709873631
Email 3038668@vip.sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free triple therapy of PI3K inhibitor (Linperlisib) combined with anti-CD20 monoclonal antibody (Obinutuzumab) and BCL-2 inhibitor (Venetoclax) in R/R BV-MCL patients.


Description:

This is a single arm, open label, national multicenter clinical study that included 10 cases of relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL). The aim was to evaluate the efficacy of a chemotherapy free triple therapy consisting of PI3K inhibitor (Linperlisib) combined with anti-CD20 monoclonal antibody (Obinutuzumab) and BCL-2 inhibitor (Venetoclax) in patients with R/R BV-MCL. It is divided into a combined induction period and a maintenance treatment period. All enrolled patients receive the following combined treatment: combined induction period: Linperlisib: 80 mg, orally (pre - and post meal), once a day; Obinutuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Venetoclax: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle). Every 28 days, there are a total of 6 cycles. Maintenance treatment period: Linperlisib: 80 mg, oral (both before and after meals), once a day; Venetoclax: 400 mg, oral, once daily. Cycle every 28 days. After 6 cycles of combined treatment, the efficacy is evaluated according to the Lugano2014 standard. If complete remission (CR) or partial remission (PR) is achieved, maintenance treatment with a combination of 80 mg of linprixate and 400 mg of vinclair is administered every 28 days until disease progression, intolerable toxicity, or other reasons lead to discontinuation. If it is stable disease (SD) and progressive disease (PD), patients will be excluded from the group. The main research endpoint is Objective Response Rate (ORR). Secondary study endpoints include progression free survival (PFS); Overall survival (OS), duration of response (DOR), and safety: incidence and severity of adverse events (AE) and severe adverse events (SAE). Safety: incidence and severity of adverse events (AE) and severe adverse events (SAE).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date December 1, 2026
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years old; - Mother cell type mantle cell lymphoma (BV-MCL) confirmed by histopathological and immunophenotypic analysis; - The Eastern Oncology Collaborative Group (ECOG) scored 0-2 on physical fitness status; - Expected lifespan = 3 months - There is at least one measurable lesion: the longest diameter (LDi) of lymph node lesions is = 1.5 cm, or the LDi of extralymph node lesions is = 1 cm, or splenomegaly, or bone marrow involvement with or without malignant lymphocytosis; - Have not received treatment with PI3K inhibitors and BCL-2 inhibitors in the past; Having sufficient bone marrow and organ functions; - Having sufficient bone marrow and organ functions; - All screening period laboratory tests must be conducted according to the requirements of the plan, and must be conducted within 7 days before enrollment. The values of laboratory tests conducted for screening must meet the following criteria: Blood routine examination (no blood transfusion, no use of granulocyte colony-stimulating factor (G-CSF), no medication correction within 14 days prior to screening): 1. Hemoglobin (Hb) = 80 g/L; 2. Neutrophils (ANC) = 1.0 × 109/L; 3. Platelet count (PLT) = 75 × 109/L; Biochemical examination: 1. TBIL<1.5 × Upper limit of normal range (ULN); 2. Glutamate alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 × ULN; 3. Serum creatinine (Cr) = 1.25 × ULN or endogenous creatinine clearance rate = 60 mL/min (Cockcroft Gault formula); Coagulation function (unless the subject is receiving anticoagulant therapy and the coagulation parameters (PT/INR and APTT) are within the expected range of anticoagulant therapy at the time of screening): 1. International normalized ratio (INR) = 1.5 × ULN; 2. Activated partial thromboplastin time (APTT) = 1.5 × ULN; - Those who have not participated in clinical trials of other drugs within the 4 weeks prior to enrollment; - Women with a possibility of pregnancy must undergo a serum pregnancy test within 7 days before the first medication, and the result is negative. They are willing to Intended to use efficient methods of contraception during the trial period and within 1 year after the last administration of the investigational drug. For male subjects whose partners are women of childbearing age, they should undergo surgical sterilization or agree to use high-efficiency contraception methods during the trial period and 1 year after the last administration of the trial drug; - The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up. Exclusion Criteria: - Patients who have received any targeted PI3K or BCL treatment before enrollment; - History of other primary invasive malignant tumors that have not been relieved or have not been relieved for more than 3 years; - Those with involvement of the central nervous system (meninges or brain parenchyma); - Individuals who are known to have allergies to any medication in the study; - Participated in clinical trials of other drugs within 4 weeks prior to the start of the study; - Pregnant or lactating women; - Individuals with active infections, excluding fever related to tumor B symptoms; - Concomitant diseases and medical history: 1. There are multiple factors that affect oral medication, such as inability to swallow, chronic diarrhea, and intestinal obstruction 2. Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders; 3. Subjects with any severe and/or uncontrolled diseases, including: 1. Poor blood pressure control (systolic blood pressure = 150 mmHg or diastolic blood pressure = 100 mmHg); 2. Suffering from = grade 2 myocardial ischemia or myocardial infarction, arrhythmia [including QTc = 450ms (male), QTc = 470ms (female)], and = grade 2 congestive heart failure [NYHA classification]; 3. Active interstitial pneumonia or other chronic lung diseases leading to severe impairment of lung function, defined as FEV1 and DLCOc<60% of normal predicted values; 4. Liver abnormalities; 5. Decompensated cirrhosis (Child Pugh liver function rating of B or C) 6. Known clinically significant history of liver disease. Including viral hepatitis, known carriers of hepatitis B virus (HBV) must exclude active HBV infection, i.e. HBV DNA positivity (>2500 copies/mL or>500 IU/mL, and above the upper limit of normal values); Known hepatitis C virus infection (HCV) and HCV RNA positivity (>1×103copies/mL). Note: hepatitis B HBsAg positive subjects who meet the inclusion conditions, whether their HBV DNA is measurable or not, need to continue antiviral treatment (nucleoside analogues are recommended) and regularly monitor HBV DNA; For subjects with positive HBcAb but negative HBsAg in hepatitis B, HBV DNA should be monitored regularly and preventive antiviral treatment should be recommended; Hepatitis C patients need to regularly monitor HCV RNA. 7. Renal failure requiring hemodialysis or peritoneal dialysis; 8. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites that require repeated drainage; 9. Poor control of diabetes (FBG>10 mmol/L); 10. Urine routine indicates urine protein =++, and it is confirmed that the 24-hour urine protein quantification is greater than 1.0 g; - Have a history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; - According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study. Unable to understand the nature of the research or disagrees to sign an informed consent form; - The researcher evaluates other situations that are not suitable for inclusion in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Linperlisib in combination with Obinutuzumab and Venetoclax
Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles? Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.

Locations

Country Name City State
China The Second Hospital Dalian Medical University Dalian Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Dalian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) according to the RECIST 1.1 The ORR rate of patients with Linperlisib in combination with Obinutuzumab and Venetoclax for relapsed and refractory blastoid variant of mantle cell lymphom At the end of Cycle 6 (each cycle is 28 days)
Secondary Progression-free survival (PFS) The time from the start of clinical trials to the occurrence (in any aspect) of tumor progression or death due to any reason From date of enrollment until the date of first documented progression and loss of follow-up or date of death from any cause, whichever came first, assessed up to 24 months
Secondary Overall survival (OS) The time from the start of tumor treatment to (for any reason) death. From date of enrollment until the date of first date of death from any cause, expected evaluation period of up to 48 months
Secondary Duration of Overall Response (DOR) The time from the first judgment of complete remission (CR) or partial remission (PR) to the discovery of disease progression (PD). From date of the time from the first assessment of the tumor as CR or PR to the first assessment as PD (Progressive Disease) or death from any cause,assessed up to 24 months
Secondary Adverse event (AE) Refers to adverse medical events that occur in the clinical trial process of the subject Record any adverse events starting from the first medication use until the end of the safety follow-up period. The evaluation period shall not exceed 24 months.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1